Biology / Biotechnology Technology Offers

UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera

Immunoglobulin Y Purification, Its Products And Uses This invention describes a purification process of immunoglobulin Y from egg yolk in three stages, by applying precipitation methods, liquid-liquid extraction and ultracentrifugation. The present process allows to obtain immunoglobulin Y of high quality and with a purity >95%, in a simple and economic way, and applicable at an industrial scale.

Immunoglobulin Y Purification, Its Products And Uses

Consejo Superior de Investigaciones Científicas posted this:

Benzothiazole Derivatives as CK-1 Inhibitors for the Treatment of Amyotrophic Lateral Sclerosis CSIC has synthesized a family of benzothiazoles which acts as casein kinase 1 (CK-1) inhibitors. Therefore, these compounds are useful for the treatment of diseases related to circadian rhythm and neurodegenerative, inflammatory, autoimmune, neurological and psychiatric diseases where CK-1 is relevant. Furthermore, these compounds induce cell regeneration. Pharmaceutical companies interested in a patent licence are sought for.

Benzothiazole Derivatives as CK-1 Inhibitors for the Treatment of Amyotrophic

Consejo Superior de Investigaciones Científicas posted this:

Microorganism and method to produce urolithins Professor Francisco Tomas group at CEBAS-CSIC has isolated and characterized the first urolithins- producing microorganism from ellagic acid and ellagitannins present in the diet. A urolithin producing method based on the use of the mentioned microorganism has been developed and both, the microorganism and the method are part of a Spanish priority patent application assigned to CSIC. Biotech companies, functional food or nutraceutical companies are sought for license and/or development agreements. An offer for Patent Licensing

Microorganism and method to produce urolithins

Consejo Superior de Investigaciones Científicas posted this:

OPTOBIOTICS: Novel antibacterial proteins activated by blue light CSIC has developed a chimeric protein that, when expressed in bacteria, changes its structure upon absorption of blue light, thus generating protein aggregates (amyloids) that inhibit bacterial growth Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement An offer for Patent Licensing

OPTOBIOTICS: Novel antibacterial proteins activated by blue light

Consejo Superior de Investigaciones Científicas posted this:

Continuous indoor rearing of Philaenus spumarius, the main European vector of Xylella fastidiosa CSIC has developed a methodology to rear the meadow spittlebug Philaenus spumarius (L.) (Hemiptera, Aphrophoridae) in control climatic conditions in the laboratory allowing the supply of nymphs and adults before they become available in the field. This continuous indoor-rearing protocol could facilitate studies on the biology, ecology and management of P. spumarius and on the transmission of Xylella fastidiosa. Innovative and research partners from the agro sector are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Continuous indoor rearing of Philaenus spumarius, the main European vector of Xylella fastidiosa

Consejo Superior de Investigaciones Científicas posted this:

Identification of particles and/or cells in suspension using a mechano-optical system CSIC has developed a sample analyzing system that can identify particles and/or biological cells in aqueous suspension or in physiological medium. The system allows simultaneously measuring the mass and light scattering of the particles in suspension in real time. This technology has been used to distinguish different cell lines, making it useful for diagnosing diseases. Industrial partners manufacturers of lab equipment are sought to collaborate through a patent license agreement. An offer for Patent Licensing

Identification of particles and/or cells in suspension using a mechano-optical system

Yissum - Research Development Company of the Hebrew University posted this:

Naturally Occurring Compounds for Treating Pathogenic Factors Common to Cystic Fibrosis Cannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720

Yissum - Research Development Company of the Hebrew University posted this:

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy Dr. Zvika Granot, from the School of Medicine-IMRIC-Developmental Biology and Cancer Research, is working on a innovative approach for Neutrophil specific targeting of TGF-beta signaling as a novel anti-cancer therapy (see attached summary and several papers) Project ID : 6-2015-4241

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy

Yissum - Research Development Company of the Hebrew University posted this:

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease A New Paradigm for Combating Infectious Disease in the Age of Antibiotic Resistance. Phage Therapy offers significant advantages: 1) Natural- Harnessing nature’s own enemy against bacteria 2) Smart kinetics Phages grow with bacteria and disappear in its absence 3) Can be manipulated (unlike antibiotics) Engineered / evolutionary developed 4) Efficient against biofilm Chain reaction of the phages 5) Do not harm the microbiome Highly specific to the target pathogen. Hazan's approach for a Personalized Phage Therapy suggests an adaptive and dynamic cocktail of phages and antibiotics , that are specially tailored using AI and machine learning prediction. Hazan et.al. offer a constantly increasing “Bank” of phages. Project ID : 43-2019-10746

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease

Yissum - Research Development Company of the Hebrew University posted this:

Novel Drug Delivery System of Large Molecules for Localized Sustained Release Novel Drug Delivery System of Large Molecules for Localized Sustained Release Project ID : 6-2018-4643

Yissum - Research Development Company of the Hebrew University posted this:

Novel Chimeric System for Targeted Killing of Lymphocytic Cancer Cells Novel Chimeric Protein utilizing components of the Ubiquitin-Proteasome System for targeted killing of Lymphocytic Cancer Cells Project ID : 6-2018-4687

Yissum - Research Development Company of the Hebrew University posted this:

New Methodology to Control Calcium Carbonate Morphology and Material State New Methodology to Control Calcium Carbonate Morphology and Material State Project ID : 6-2018-4599

Yissum - Research Development Company of the Hebrew University posted this:

New Target for the Treatment of Abdominal Obesity New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway Project ID : 7-2018-4658

Yissum - Research Development Company of the Hebrew University posted this:

Novel Method for Identifying Personalized Anti-Cancer Drug Combinations NanoCode - Identifying Best Fit Cancer Drug Combinations In-Vivo Project ID : 6-2019-6704

Yissum - Research Development Company of the Hebrew University posted this:

miRNA-Responsive Drug-Loaded NMOFs for the Targeted Treatment of Cancer miRNA-Responsive Drug-Loaded NMOFs for the Targeted Treatment of Cancer Project ID : 6-2019-6706

miRNA-Responsive Drug-Loaded NMOFs for the Targeted Treatment of Cancer

1
2
3
4
5